BR112013026004B1 - Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante - Google Patents

Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante Download PDF

Info

Publication number
BR112013026004B1
BR112013026004B1 BR112013026004-1A BR112013026004A BR112013026004B1 BR 112013026004 B1 BR112013026004 B1 BR 112013026004B1 BR 112013026004 A BR112013026004 A BR 112013026004A BR 112013026004 B1 BR112013026004 B1 BR 112013026004B1
Authority
BR
Brazil
Prior art keywords
gdnf
variant
human
seq
variants
Prior art date
Application number
BR112013026004-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013026004A2 (pt
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O´Bryan
Rosamund Carol Smith
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of BR112013026004A2 publication Critical patent/BR112013026004A2/pt
Publication of BR112013026004B1 publication Critical patent/BR112013026004B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
BR112013026004-1A 2011-04-11 2012-04-03 Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante BR112013026004B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
US61/474,024 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (2)

Publication Number Publication Date
BR112013026004A2 BR112013026004A2 (pt) 2016-11-29
BR112013026004B1 true BR112013026004B1 (pt) 2020-09-29

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026004-1A BR112013026004B1 (pt) 2011-04-11 2012-04-03 Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante

Country Status (28)

Country Link
US (1) US9243046B2 (https=)
EP (1) EP2696889B1 (https=)
JP (1) JP6093345B2 (https=)
KR (1) KR101554799B1 (https=)
CN (1) CN103635201B (https=)
AU (1) AU2012243178B2 (https=)
BR (1) BR112013026004B1 (https=)
CA (1) CA2833158C (https=)
CY (1) CY1119750T1 (https=)
DK (1) DK2696889T3 (https=)
EA (1) EA025129B1 (https=)
ES (1) ES2656020T3 (https=)
HR (1) HRP20171993T1 (https=)
HU (1) HUE036239T2 (https=)
IL (1) IL228102A (https=)
LT (1) LT2696889T (https=)
ME (1) ME02849B (https=)
MX (1) MX337206B (https=)
NO (1) NO2696889T3 (https=)
PL (1) PL2696889T3 (https=)
PT (1) PT2696889T (https=)
RS (1) RS56639B1 (https=)
SG (1) SG193483A1 (https=)
SI (1) SI2696889T1 (https=)
TW (1) TWI583698B (https=)
UA (1) UA112981C2 (https=)
WO (1) WO2012141936A1 (https=)
ZA (1) ZA201306556B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454886A1 (en) 2016-05-13 2019-03-20 Instituto de Medicina Molecular Methods of treating diseases associated with ilc3 cells
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
EP2393832B1 (en) * 2009-02-06 2015-07-08 Pepscan Systems BV Truncated cystine-knot proteins

Also Published As

Publication number Publication date
PL2696889T3 (pl) 2018-04-30
ES2656020T3 (es) 2018-02-22
AU2012243178B2 (en) 2016-09-29
NZ614325A (en) 2015-07-31
JP6093345B2 (ja) 2017-03-08
WO2012141936A1 (en) 2012-10-18
RS56639B1 (sr) 2018-03-30
DK2696889T3 (en) 2018-01-22
NO2696889T3 (https=) 2018-04-14
HUE036239T2 (hu) 2018-06-28
BR112013026004A2 (pt) 2016-11-29
CY1119750T1 (el) 2018-06-27
EA201370204A1 (ru) 2014-02-28
PT2696889T (pt) 2018-02-05
AU2012243178A1 (en) 2013-09-05
CA2833158C (en) 2018-07-17
CN103635201B (zh) 2016-11-09
UA112981C2 (uk) 2016-11-25
CA2833158A1 (en) 2012-10-18
IL228102A0 (en) 2013-09-30
EP2696889B1 (en) 2017-11-15
JP2014512369A (ja) 2014-05-22
LT2696889T (lt) 2018-02-12
TW201245220A (en) 2012-11-16
IL228102A (en) 2017-04-30
ZA201306556B (en) 2015-03-25
SG193483A1 (en) 2013-10-30
EA025129B1 (ru) 2016-11-30
KR101554799B1 (ko) 2015-09-21
HRP20171993T1 (hr) 2018-02-09
EP2696889A1 (en) 2014-02-19
TWI583698B (zh) 2017-05-21
US20130324474A1 (en) 2013-12-05
KR20130131470A (ko) 2013-12-03
US9243046B2 (en) 2016-01-26
MX337206B (es) 2016-02-17
MX2013011919A (es) 2014-03-27
CN103635201A (zh) 2014-03-12
ME02849B (me) 2018-01-20
SI2696889T1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
JP6940636B2 (ja) プロトキシン−ｉｉ変異体及びその使用方法
BRPI0911385B1 (pt) Polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
EP2054434A1 (en) Myostatin antagonists
ES2888799T3 (es) Variantes de Protoxina-II y métodos de uso
EP3265476A2 (en) Protoxin-ii variants and methods of use
Smith et al. Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF
US20100183588A1 (en) Mutated Netrin-4, Fragments Thereof And Their Use As Medicines
BR112013026004B1 (pt) Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante
US10414808B2 (en) Huwentoxin-IV variants and methods of use
ES2259458T3 (es) Persefina humana.
Hernychová et al. The C-type lectin-like receptor Nkrp1b: Structural proteomics reveals features affecting protein conformation and interactions
NZ614325B2 (en) Variants of human gdnf
HK1190308B (en) Variants of human gdnf
HK1190308A (en) Variants of human gdnf
Carucci Towards structure determination of protein-ligand complexes of TrkA and TrkB receptors: from protein production to crystal optimization
AU2013231037B2 (en) Myostatin antagonists
US10435450B2 (en) MET receptor agonist proteins

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/04/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.